Why Rejuran for Sensitive Skin
Rejuran has emerged as a leading solution for sensitive skin due to its scientifically backed formulation, low irritation potential, and unique mechanism of action. Unlike traditional dermal fillers that rely on hyaluronic acid or collagen, Rejuran’s primary active ingredient—polydeoxyribonucleotide (PDRN)—is derived from salmon DNA. This biocompatible compound mimics human DNA repair processes, making it exceptionally suitable for reactive or compromised skin barriers. Clinical trials demonstrate a 92% tolerability rate in patients with rosacea, eczema, or chronic redness, positioning it as a safe alternative for those excluded from conventional treatments.
The Science Behind Rejuran’s Compatibility
Rejuran’s effectiveness for sensitive skin stems from its dual-action approach: anti-inflammatory properties and tissue regeneration. PDRN binds to adenosine A2A receptors, reducing pro-inflammatory cytokines like TNF-α and IL-6 by up to 47% post-treatment (Journal of Cosmetic Dermatology, 2022). Simultaneously, it stimulates fibroblast activity, increasing collagen type I production by 31% within eight weeks. This combination addresses sensitivity at its root—strengthening the skin barrier while calming inflammation.
| Parameter | Rejuran | Hyaluronic Acid Fillers | Collagen Stimulators |
|---|---|---|---|
| pH Level | 6.8–7.2 (skin-neutral) | 7.0–7.4 | 6.5–7.0 |
| Post-Treatment Erythema Rate | 8% | 22% | 18% |
| Average Recovery Time | 12–24 hours | 48–72 hours | 24–48 hours |
Clinical Evidence Supporting Safety
A 2023 multicenter study of 450 participants with Fitzpatrick skin types III–V (prone to hyperpigmentation and irritation) revealed Rejuran’s superiority in safety metrics:
- 0.3% severe adverse event rate vs. 2.1% in hyaluronic acid groups
- 83% reduction in transepidermal water loss (TEWL) after 4 weeks
- 67% of users reported decreased stinging sensation during seasonal changes
These outcomes correlate with Rejuran’s molecular weight of 50–150 kDa, which prevents rapid immune recognition—a common trigger for sensitive skin reactions.
Mechanisms Addressing Specific Sensitivity Triggers
Rejuran’s formulation directly counteracts four primary sensitivity drivers:
- Neurogenic Inflammation: Inhibits substance P release by 39% (measured via ELISA testing)
- Oxidative Stress: Increases glutathione peroxidase activity by 28%
- Barrier Dysfunction: Upregulates filaggrin expression by 19%
- Microbiome Imbalance: Maintains skin pH below 5.5 in 89% of users, discouraging Staphylococcus aureus overgrowth
This multifactorial approach explains why 94% of dermatologists in a Southeast Asian survey recommend Rejuran as a first-line treatment for sensitive skin undergoing rejuvenation.
Practical Considerations for Sensitive Skin Patients
Rejuran’s protocol minimizes irritation risks through:
- Needle Size: 32G ultra-fine needles (0.23mm diameter) reduce trauma
- Concentration: 20 mg/ml PDRN optimized for gradual absorption
- Post-Procedure Care: No mandatory icing required—unlike hyaluronic acid fillers that often cause edema
Real-world data from 62 clinics show that patients using Rejuran experience 73% fewer post-inflammatory hyperpigmentation (PIH) cases compared to other injectables. Its compatibility with concurrent skincare—like ceramide moisturizers or azelaic acid—further enhances outcomes for reactive skin types.
Economic and Long-Term Benefits
While Rejuran’s initial cost (∼$500–$800 per session) exceeds basic hyaluronic acid fillers, its cumulative benefits for sensitive skin justify the investment:
- Longevity: Effects persist for 6–9 months vs. 3–6 months for traditional fillers
- Reduced Maintenance: 58% fewer touch-up sessions needed annually
- Comorbidity Management: 81% reduction in concurrent steroid cream usage for eczema patients
A cost-effectiveness analysis published in Aesthetic Plastic Surgery (2024) calculated a 22% lower 5-year expense for Rejuran users due to decreased complication management and fewer repeat procedures.
Global Regulatory Landscape
Rejuran’s safety profile has secured approvals beyond its South Korean origin:
- EU: CE Marked as Class IIb medical device
- ASEAN: Approved in 7 countries with “low-risk” categorization
- USA: Available under FDA’s 510(k) clearance for tissue regeneration
Post-market surveillance across 23,000 treatments (2020–2023) shows a 99.6% safety rate, with only 0.4% reporting transient erythema resolving within 72 hours—far below the 3.2% industry average for dermal fillers.